MicroRNA-506-3p increases the response to PARP inhibitors and cisplatin by targeting EZH2/β-catenin in serous ovarian cancers

Chemo-resistance is an important barrier to effective treatment of ovarian cancer. Poly (ADP-ribose) polymerase (PARP) inhibitors are currently promising targeted drugs used to treat BRCA-mutant ovarian cancer. Ovarian cancer patients with BRCA 1/2 mutations appear to benefit better from PARP inhibi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Transl Oncol
Hlavní autoři: Sun, Yue, Wu, Jing, Dong, Xiaoying, Zhang, Jingzi, Meng, Chao, Liu, Guoyan
Médium: Artigo
Jazyk:Inglês
Vydáno: Neoplasia Press 2020
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7770486/
https://ncbi.nlm.nih.gov/pubmed/33360300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2020.100987
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky